Current research projects include the Adeno-associated virus serotype 9 (AAV9): PKP2 gene therapy project, the TN-401 AAV9-Based Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), etc. These treatments prevent ventricular remodeling, delay the decline in left ventricular function, and reduce the incidence of arrhythmias. Here, PKP2 is linked to arrhythmogenic right ventricular cardiomyopathy.